SARDs are a heterogeneous group of disorders characterized by dysregulation of the immune system, that starts to turn against the body’s own tissues. Major SARDs include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjögren’s syndrome. These diseases can affect multiple organs and share common symptoms such as fatigue, fever, joint pain and skin rash. Diagnosis relies on a combination of clinical assessment and specific autoantibody tests. Early diagnosis is crucial to initiate appropriate therapy and slow down disease progression.
Anti-SRP autoantibodies (Signal Recognition Particle) are directed against the cytoplasmic ribonucleoprotein (RNP) SRP complex, involved in the recognition and transport of newly synthesised proteins to the endoplasmic reticulum. Anti-SRP antibodies are mainly associated with the polymyositis (PM) phenotype and with a reduced likelihood of cutaneous involvement. They are strongly correlated with severe necrotising myopathy, with patients rapidly developing progressive muscle weakness and severe disability within a few months of disease onset. Their serological detection is therefore highly relevant for identifying distinct clinical phenotypes, stratifying prognosis, and guiding therapeutic management.
Serum, EDTA plasma, heparin plasma, citrate plasma
Immunoblot
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.